Daniele Laszlo

Medicine & Life Sciences

1. Granulocyte Colony-Stimulating Factor 100%
2. Rituximab 97%
3. Bone Marrow Transplantation 95%
4. Bone Marrow 92%
5. plerixafor octahydrochloride 90%
6. Drug Therapy 76%
7. Non-Hodgkin's Lymphoma 72%
8. Lymphoma 67%
9. Transplantation 64%
10. Homologous Transplantation 62%
11. Multiple Myeloma 57%
12. Graft vs Host Disease 56%
13. Induction Chemotherapy 56%
14. Hematopoietic Stem Cell Mobilization 55%
15. Photopheresis 53%
16. Peripheral Blood Stem Cells 52%
17. Germ Cell and Embryonal Neoplasms 51%
18. Anaplastic Large-Cell Lymphoma 47%
19. Multicenter Studies 46%
20. Survival 45%
21. Paclitaxel 44%
22. Follicular Lymphoma 43%
23. Therapeutics 42%
24. Progression-Free Survival 40%
25. Transplants 40%
26. Chlorambucil 39%
27. Waldenstrom Macroglobulinemia 35%
28. Leukemia 35%
29. Anaplastic Lymphoma Kinase 35%
30. Seminoma 33%
31. Autologous Transplantation 32%
32. BK Virus 30%
33. Blood Component Removal 30%
34. Cohort Studies 29%
35. Hematopoietic Stem Cells 29%
36. Cystitis 29%
37. Marginal Zone B-Cell Lymphoma 29%
38. Transplant Recipients 28%
39. Filgrastim 28%
40. Chronic Hepatitis C 27%
41. 2'-deoxyadenosine 26%
42. Cladribine 25%
43. Lymphoma, Large B-Cell, Diffuse 24%
44. Hepacivirus 24%
45. Peripheral T-Cell Lymphoma 24%
46. Human Herpesvirus 6 23%
47. Neoplasms 22%
48. Salvage Therapy 22%
49. T-Lymphocytes 21%
50. Prospective Studies 21%